Riluzole use and reasons for non-use in people with amyotrophic lateral sclerosis in Aotearoa New Zealand
People with ALS in New Zealand have low uptake of riluzole, despite its survival benefits. Prescribers and people with ALS need up-to-date information about riluzole's benefit-risk profile to increase uptake and confidence in prescription and use. Liquid riluzole is needed in New Zealand to aid uptake.
Authors
- James Cleland
- Stephen Buetow (ORCID: https://orcid.org/0000-0002-9771-248X)
- Joanna Hikaka (ORCID: https://orcid.org/0000-0001-6792-6607)
- Natalie Gauld
- Sarah Buchanan
- Chris Frampton
Institutions
- University of Auckland (NZ)
- Dunedin Public Hospital (NZ)
- Tauranga Hospital (NZ)
- University of Otago (NZ)
Publication Details
- Journal
- New Zealand Medical Journal
- Published
- 2026-01-28
- DOI
- https://doi.org/10.26635/6965.7238
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00